Crystal Run Healthcare and Circuit Clinical establish partnership to bring clinical trial opportunities to patients

BUFFALO, N.Y. and MIDDLETOWN, N.Y., Aug. 31, 2021 - Circuit Clinical®, an integrated research platform dedicated to bringing clinical research as a care option to everyone, and Crystal Run Healthcare, one of the fastest-growing multi-specialty group practices in the country, announced a partnership that will allow Crystal Run Healthcare’s patient population to participate in clinical research.  

Data vs. Insights: Meeting Clinicians and Patients at the Point of Care

Throughout the past decade, I have focused on developing clinical content and decision support tools to help clinicians identify high-risk patients and deliver guideline-based care, with an emphasis on managing complex chronic diseases, including chronic kidney disease (CKD), cardiovascular disease and diabetes. Laboratory results are critical for diagnosing and monitoring a patient's condition, but my experiences in practice and in talking with other clinicians underscore the need for laboratory insights that offer a clearer picture of a patient's health. There is also a need for corresponding information that enhances patient understanding of laboratory test results to increase engagement and compliance with treatment plans. 

Implementation of the new ASCO/CAP guidelines for HER2 testing in the clinical laboratory

Quantitative measurements reveal elevated levels of HER2-HER3 heterodimers in brain metastases compared to matched primary breast cancers

Runs of Homozygosity (ROH) reveal that segmental-UPD occurs as a result of recombination mediated repair of genomic imbalance

Epi proColon®, Septin 9 gene methylation detection assay as a screening tool for colorectal cancer

Unique 9q34 rearrangements in T-ALL: Elucidation and characterization by microarray analysis, RNA sequencing and FISH

EGFR gene mutation analysis in non-small cell lung cancer using cobas® assay in FFPE and plasma specimen types

Acute promyelocytic leukemia with atypical karyotype and FLT3-ITD mutation is associated with inferior clinical outcome